AETHLON MEDICAL INC — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Aethlon Medical (market cap ~$5.7M) reported Q1 FY2027 ended June 30, 2026 with cash of $4.9M and operating expenses of $1.6M (down 11.9% YoY). Post-quarter, the company raised ~$4.0M gross in a public stock offering, giving total liquidity of ~$8.9M. Management states this funding is sufficient for at least 12 months of operations. Clinically, the company dosed the first participant in the third/final cohort of its Phase 1 oncology study in Australia and published a Long COVID manuscript on extracellular vesicles.
Why this rating
Post-quarter $4M raise nearly doubles near-term liquidity for a $5.7M company, materially extending runway. Clinical progress (Phase 1 dosing, publication) is modest but adds credibility. Runway uncertainty removed for 12 months—significant for microcap survival.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.